EXTON, Pa., Jan. 6 /PRNewswire-FirstCall/ -- Kensey Nash Corporation will present at the Sidoti Third Annual Palm Beach Emerging Growth Institutional Investor Forum at the Ritz-Carlton in Palm Beach on Tuesday, January 17, 2006.
Joseph W. Kaufmann, Kensey Nash’s President & CEO, will deliver the Company’s presentation, beginning at approximately 10:25 a.m. (EST). The presentation materials will be available on the company’s website (http://www.kenseynash.com) beginning at 10:25 a.m. (EST) on Tuesday, January 17, 2006 and will remain on the website for approximately two weeks.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading developer and manufacturer of medical devices with applications in the cardiology, orthopaedics, spine, drug and biologics delivery, periodontal/dental, surgical and wound care markets. The Company’s endovascular product platform currently includes the TriActiv(R) System, a novel embolic protection system, which is approved for sale in the U.S., as well as the TriActiv(R) FX(TM) System, the second generation of the TriActiv(R) System, which is approved for sale in the European Union and has been studied in a clinical trial to gain regulatory approval in the U.S. The Company was a pioneer in the field of absorbable biomaterials-based products and in arterial puncture closure, as the inventor and developer of the Angio- Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Statements made during the presentation that are not historical facts are forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that a number of important factors could cause the Company’s actual results to differ materially from those in the forward-looking statements. For a more detailed discussion of these and other factors, please see the Company’s SEC filings. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. Fluctuations in operating results may also result in fluctuations in the price of the Common stock.
Kensey Nash Corporation
CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer, KenseyNash Corporation, +1-484-713-2100
Web site: http://www.kenseynash.com/